Reasons to be cheerful:Concurrently, Botanix continues to develop its broader pipeline of products including an atopic dermatitis treatment BTX 1204, which is expected to be the subject of a patient study commencing in 4Q CY2017, as well as a range of Permetrex™ enabled products that are in early stage development with collaborators."
"
More reasons to be cheerful:
..."we are excited about the potential for BTX 1503 to be one of the first new prescription products to treat acne approved by FDA, in more than 20 years"
Got to be happy holding this one.
Ann: FDA Clears Development Path for BTX 1503, page-5
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
-0.020(5.00%) |
Mkt cap ! $689.3M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.0¢ | $2.264M | 5.785M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 790722 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 231350 | 4 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |